A 70 year-old woman visited our hospital complaining of macrohematuria. She had undergone augmentation ileocystoplasty for tuberculous bladder atrophy 50 years previously. CT and cystoscopy showed tumor at the ileovesical anastomosis. She underwent a partial cystectomy. The pathological diagnosis was adenocarcinoma of the ileal segment. Recurrence was observed with rapid progression. The patient died 8 months after the operation. In Japanese literature, 43 cases of carcinoma arising in augumented bladder have been reported. Average period to the diagnosis of the cancer from the ileocystoplasty is 33 years. The period of our case was 50 years, the longest in 43 cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5980/jpnjurol.105.207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.
Endocr Oncol
January 2024
Department of Oncology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Summary: Craniopharyngiomas (CPs) are rare brain epithelial tumours arising in the suprasellar region, infiltrating adjacent areas causing visual loss, panhypopituitarism, cognitive deficits and morbid obesity. Papillary CPs (PCPs) harbour in 94% BRAF mutation cases. Two patients with PCP and BRAF V600E mutations but with different tumour status were treated with BRAF and MEK inhibitors.
View Article and Find Full Text PDFThe Microenvironment in DCIS and Its Role in Disease Progression.
Adv Exp Med Biol
January 2025
Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, London, UK.
Ductal carcinoma in situ (DCIS) accounts for ~20% of all breast cancer diagnoses but whilst known to be a precursor of invasive breast cancer (IBC), evidence suggests only one in six patients will ever progress. A key challenge is to distinguish between those lesions that will progress and those that will remain indolent. Molecular analyses of neoplastic epithelial cells have not identified consistent differences between lesions that progressed and those that did not, and this has focused attention on the tumour microenvironment (ME).
View Article and Find Full Text PDFLiposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma.
Drugs
January 2025
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Liposomal irinotecan (Onivyde), also known as liposomal pegylated irinotecan, has been developed with the intent of maximising anti-tumour efficacy and minimising drug-related toxicities compared with conventional formulations of this topoisomerase 1 inhibitor. In combination with fluorouracil, leucovorin and oxaliplatin (NALIRIFOX), liposomal irinotecan is approved in the USA and the EU for first-line therapy of eligible patients with metastatic pancreatic adenocarcinoma. In a phase III clinical trial, NALIRIFOX significantly improved overall survival (OS) and progression free survival (PFS) compared with gemcitabine plus nanoparticle albumin bound paclitaxel (nab-paclitaxel) as first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
View Article and Find Full Text PDFPharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.
Cancer Chemother Pharmacol
January 2025
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Purpose: After initial approval of lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), it has also shown promising outcomes in among others metastatic renal cell carcinoma (mRCC). Given that trial populations typically do not represent routine clinical care populations, questions arise about how applicable trial outcomes are in clinical practice. This study aims to compare the pharmacokinetics (PK), toxicity patterns, and survival data of lenvatinib in a real-world cohort with DTC and mRCC to those observed in pivotal clinical trials.
View Article and Find Full Text PDFColorectal metastasis from gastric cancer: insights from a 14-year case series at a tertiary hospital.
J Gastrointest Oncol
December 2024
Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
Background: Colorectal metastasis from gastric cancer is very rare, with existing literature limited to only a few case reports. This study was designed to investigate the clinicopathological features and prognosis of colorectal metastasis arising from gastric cancer.
Methods: Patients with colorectal metastasis from gastric cancer who underwent surgical intervention at a single tertiary hospital between January 2010 and June 2023 were included, and their clinicopathological characteristics and oncologic outcomes were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!